Mehdi Mirsaeidi is a Respiratory physician. OpenAlex indexes 385 publications with 14,415 citations (h-index 55); ClinicalTrials.gov lists 2 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Pulmonary Disease profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1601 Trinity St
Austin, TX 787121765
Telephone
833-882-2737Provider last certified this registry record 18 Nov 2025.
Clinical trials
- Association Between Cancer and Sarcoidosis
Sponsor: University of Miami
- Treatment Outcomes in Patient With Nontuberculous Mycobacterial Disease
Sponsor: University of Illinois at Chicago
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Mannkind CorporationProgram year20251 payment
- Mallinckrodt Hospital Products Inc.Program year202513 payments
- United Therapeutics CorporationProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
74.3%Corticosteroid33.2%Trelegy Ellipta66%Symbicort18%Breyna16%Part D<11 patientsbeta2-Adrenergic Agonist26.2%Albuterol Sulfate Hfa80%Ventolin Hfa20%Part D<11 patients+ 2 more classes in this area
Anti-infectives
13.6%Macrolide Antimicrobial13.6%Azithromycin100%Part D<11 patientsMetabolism & gastrointestinal
12.1%Corticosteroid12.1%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
Proceedings of the National Academy of Sciences
2022 - Diagnostic, Prognostic, and Therapeutic Roles of Gut Microbiota in COVID-19: A Comprehensive Systematic Review
Frontiers in Cellular and Infection Microbiology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Fernando Martinez, MD
University of Massachusetts Chan Medical School
David Gozal, MD
Marshall University
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”